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Abstract
Tumors are defined by their intense proliferation, but sometimes cancer cells turn senescent and stop replicating. In the
stochastic cancer model in which all cells are tumorigenic, senescence is seen as the result of random mutations, suggesting
that it could represent a barrier to tumor growth. In the hierarchical cancer model a subset of the cells, the cancer stem cells,
divide indefinitely while other cells eventually turn senescent. Here we formulate cancer growth in mathematical terms and
obtain predictions for the evolution of senescence. We perform experiments in human melanoma cells which are
compatible with the hierarchical model and show that senescence is a reversible process controlled by survivin. We
conclude that enhancing senescence is unlikely to provide a useful therapeutic strategy to fight cancer, unless the cancer
stem cells are specifically targeted.
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Introduction
Cancer cells are characterized by their persistent proliferation,
but just as for normal cells [1] tumor cells can go senescent, halting
their growth [2,3]. The molecular basis for the induction of
senescence appears to be a combination of several mechanisms
such as telomerase shortening, DNA-damage and oxidative stress
[3]. It has been suggested that senescence should be present only in
pre-neoplastic cells [3] but there is evidence that senescence
markers increase during tumor progression [4]. This is puzzling
since it is usually assumed that tumors can only grow if senescence
is avoided. Recent experiments are challenging this conventional
view of cancer, showing that only a small fraction of cancer cells,
the cancer stem cells (CSCs) [5], actively drive tumor growth. The
implications of this finding for tumor cell senescence have hitherto
not been explored.
According to the CSC hypothesis, tumors behave in analogy
with normal tissues, whose growth is controlled by a small
population of slowly replicating stem cells with the dual capacity of
either self-renewal or differentiation into the more mature cells
required by the tissue. The crucial difference between tissue stem
cells and CSCs lies in their proliferation properties. Stem cells in
tissues tend to keep their number constant either deterministically
by enforcing asymmetric division, or stochastically by balancing
proliferation and depletion probabilities [6,7]. This restriction does
not hold for CSCs. The role of CSCs has important implications
for therapeutic approaches. According to the conventional view,
the success of a treatment is measured by the number of tumor
cells killed; in contrast, according to the CSC hypothesis, only the
CSC subpopulation matters in the end for complete eradication.
First evidences for the existence of CSCs came from hematological
tumors [5] and later from solid tumors such as breast cancer [8]
and melanoma [9–16]. The presence of CSCs in melanoma is
currently debated. It was argued that to obtain reliable estimates of
the number of tumor initiating cells one should use highly
immunocompromised mice for tumor xenografts [17]. Different
groups, however, reported conflicting results with slight differences
in assay conditions and mouse models [14,17]. Furthermore,
several putative CSC markers appears to be reversibly expressed in
melanoma [18] and in breast cancer [19].
In this paper, we analyze cell senescence during the growth of
melanoma cells both in vitro and in tumor xenografts. We find
that the fraction of senescent cells increases considerably after a
few months of cultivation, slowing down the growth of the cell
population. This process is, however, only transient: after some
time senescence almost disappears and growth resumes at the
initial rate. We also show that senescence is a reversible process
controlled by survivin: by overexpressing survivin in senescent
cells, we are able to decrease senescent markers and increase cell
proliferation. These results can be interpeted in terms of the
hierarchical cancer model where only CSCs replicate indefi-
nitely and senescence reflects the loss of proliferative capacity of
other cancer cells. To prove this point we sort cancer cells
according to a putative CSC marker, ABCG2, and show that
senescence is more prevalent for negative cells, suggesting that
CSC are able to rejuvenate an otherwise senescent cell
population.
To understand quantitatively the experimental results, we
propose a mathematical model for cancer growth that is
compatible with the existence of CSCs in melanoma, provides
an unambiguous interpretation of experimental data, and
explains quantitatively the occurrence of senescence in tumors.
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While in the stochastic cancer model, senescence is due to
spontaneous mutations of tumor cells, in the hierarchical model
only CSCs replicate indefinitely and senescence reflects the loss
of proliferative capacity of other CCs. These observations can be
recast in a mathematical framework using the theory of
branching processes, a generic model for a growing population
[20,21]. Branching processes were first proposed at the end of
the XIX century and found wide application in physics and
biology with examples ranging from nuclear reactions [20] to
evolution theory [21], tissue growth [6,22–24] and cancer
progression [25,26]. The main limitation of branching processes
is that they do not account for interactions between cells which
could be relevant for the growth of a tumor, especially in vivo.
Despite this shortcoming, our model allows for a good
description of the experiments, providing an indirect confirma-
tion of the CSC hypotesis for melanoma with important
implications for therapeutic strategies based on the induction
of senescence in cancer.
Results
Hierarchical model for cancer growth
Our theory has biologically motivated ingredients characteriz-
ing the probabilities for cells to duplicate, become senescent or die:
According to the CSC hypothesis, cells are organized hierarchi-
cally, with CSCs at the top of the structure. CSCs can divide
symmetrically with rate Rd giving rise to two new CSCs with
probability p2, two CCs with probability p0, or asymmetrically
with probability p1~1{p0{p2 giving rise to a CSC and a CC.
While CSCs can duplicate for an indefinite amount of time, CCs
become senescent after a finite number of generationsM and then
eventually die rate q (Fig. 1). The model kinetics depends on the
combination E~p2{p0, the average relative increase in the
number of CSCs after one duplication, rather than on p0, p1 and
p2 separately. In normal tissues, the stem cell population should
remain constant which implies that E~0 [6,27], while in tumors
we expect Ew0.
The kinetics of the cell populations for this model can be solved
exactly. To this end, we first derive recursion relations linking the
average cell populations at each generation. Denoting by SN the
average number of CSCs after N generations, by CNk the average
number of CCs, where k~1,:::,M indicates the ‘‘age’’ of the CCs
(i.e. the number of generations separating it from the CSC from
which it originated), and by DN the average number of senescent
cells, we obtain
SN~(1zE)SN{1
CN1 ~(1{E)S
N{1
::: :: :::
CNk ~2C
N{1
k{1
DN~(1{q)DN{1z2CN{1M :
ð1Þ
These relations are derived considering that CSCs can only
originate from other CSCs either by a symmetric division – two
CSCs are generated with probability p2 – or by an asymmetric
one, in which case a single CSC is generated with probability
1{p2{p0. Hence each CSC generates an average of
2p2z1{p2{p0~1zE new CSCs. CSCs also generate CCs
(k~1) by asymmetric CSC divisions, with probability 1{p2{p0
or by symmetric CSC division with probability p0, yielding an
average of 1{p2{p0z2p0~1{E CCs. Two CCs are generated
by duplication of other normal cells with unit probability
(k~2:::M ). Senescent cells accumulate at each generation when
normal cells (with k~M ) lose the ability to duplicate and die
with probability q. Eqs. 2 can be solved explicitly. We consider
first an initial condition with CSC only (i.e. C0k~D
0~0) and
obtain
SN~(1zE)NS0
CNk ~
SN
2
1zE
 k{1
1{E
1zE
for Nwk
0 for Nƒ k
8><
>:
DN~
SN
(1{E)
Ezq
2
1zE
 M
1{
1{q
1zE
 N{M !
for NwM
0 for NƒM
8><
>:
ð2Þ
Eqs. 2 implies that the average CSC population SN grows
exponentially fast, and that after a large number of generations
(i.e. for N&M ), all cells populations, and hence the size of the
tumor, are proportional to the CSC population. This result
confirms that the population of CSCs is the driving force behind
tumor growth. Note that the population of senescent cells is also
driven by the growth of CSCs and therefore cancer growth and
senescence are inextricably linked.
To interpret experimental data, it is important to consider the
case in which the initial condition is composed of a mixed
population of CSCs and CCs. The solution in this case can be
obtained as a linear superposition of the solution of Eqs. 2 and the
solution with initial conditions S0~0, C0kw0 and D0w0. For
simplicity, we consider the case of a uniform distribution for the
ages of CSCs: C0k~D
0~c, and obtain
S^N~0
C^Nk ~
2kc for Nvk
0 for N § k
(
D^N~
c(1{q)Nzc
2
1zq
(2N{(1{q)N ) for NƒM
c(1{q)N (1z
2
1zq
(
2
1{q
 M
{1)) for NwM
8>><
>>:
ð3Þ
Author Summary
It is commonly believed that cell senescence – the loss of
replicative capacity of cells – acts as a barrier for tumor
growth. Here we follow the evolution of senescence
markers in melanoma cells and find that while most cancer
cells eventually turn senescent, this is at root irrelevant for
the long-term growth rate of a tumor. To demonstrate this,
we construct a mathematical population dynamics model
incorporating cancer stem cells which is able to reproduce
quantitatively the experimental data. Our results support
the existence of cancer stem cells in melanoma and
explain why it is difficult to fight cancer by inducing
senescence in cancer cells. Only a fraction of the cells are
susceptible to senescence, but those cells are irrelevant for
tumor growth. A successful therapeutic strategy should
instead target cancer stem cells, which are, however, likely
to be strongly resistant to drug induced senescence.
Senescent Cells in Growing Tumors
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The complete solution for the total number of cells, corresponding
to an initial condition S0w0 and C0k~D0~c, is given by
nNtot~S
NzS^Nz
XM
k~1
(CNk zC^
n
k)zD
NzD^N ð4Þ
and is plotted in Fig. 2A, while in Fig. 2B we report the fraction of
senescent cells.
Eqs.2 represent only a transient contribution to the cell
population and does not influence the asymptotic fractions (i.e.
for N&M ) of senescent cells f?SC and CSCs f?CSC which are readily
obtained dividing the results in Eqs. 2 by the total number of cells
at each generation:
f?SC~
1{E
1zq
ð5Þ
f?CSC~
qzE
1zq
1zE
2
 M
: ð6Þ
The asymptotic solutions are plotted in Fig. S1 as a function of E
for different values of q and M.
It is instructive to use the solution to compare how cells become
senescent in normal tissues and in cancers. In the long time limit,
the asymptotic fraction of senescent cells is equal to f?S ~
(1{E)=(1zq) and is independent of the number of duplications
M needed to induce senescence (see Fig. S1). For normal stem
cells, E~0 and the percentage of senescent cells is expected to be
large, reaching 100% in the limit of q~0, when senescent cells
never die. For cancer cells, Ew0 and the fraction of senescent cells
is smaller but still non-vanishing. Similarly, the CSC fraction is
given by f?CSC~
qzE
1zq
1zE
2
 M
which is smallest for normal stem
cells and increases as a function of E in tumors (see Fig. S1).
Aggressive tumors such as melanoma should be characterized by
high values of E and therefore by relatively high values of the CSC
fraction. Beside asymptotic fractions, the model allows one also to
characterize the evolution of the populations, i.e. the time-
dependent evolution of the senescent cell fractions (see Fig. 2). The
results show that the level of senescence in tumors strongly
depends on the fraction of CSCs and on time.
Growth of mesenchymal stem cells
To quantitatively confirm that the model is able to predict the
growth properties of stem cells, we first compare its results with
experimental data for normal stem cells, and then turn to cancers.
It has been shown that long-term in vitro culture of mesenchymal
stem cells (MSC) induces replicative senescence with important
implication for the therapeutic application of MSC preparations
[28,29]. In particular, the authors show a rapidly increasing
fraction of cells that are positive to b{gal, a senescence marker;
after roughly 50 days, the fraction of senescent cells reaches 80%
of the population. By looking at the growth curves for cells
extracted from donors of different ages, the authors could not
establish a correlation between senescence and aging [29].
To validate our model, we have used it to fit the growth curves
reported in Ref. [28]. In order to compare the model with the
Figure 1. Branching processes for cancer growth. At each generation, CSCs can divide symmetrically, giving rise to two CSCs with probability
p2 or to two CCs with probability p0 , or asymmetrically with probability p1~1{p2{p0 giving rise to a CSC and a CC. Cancer cells can only divide a
finite number of times M (in the figure M~3), after that they become senescent. Senescent cells die with probability q at each generation.
doi:10.1371/journal.pcbi.1002316.g001
Senescent Cells in Growing Tumors
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experiments, we should first express the evolution equations as a
function of time rather than generation number. This is easily
done introducing the rate of cell division per day Rd and replacing
in Eqs.2–3 the generation index N by Rdt, where t is time
expressed in days. In this way, Eq.4 can directly be compared with
the growth curves reported in Refs. [28,29]. In particular, we use
Eq.4 for E~0, q~0 and c~0. Under this conditions the
expression reduces to a much simpler form
ntot(t)~
S02Rd t for tƒM=Rd
S02M (1zRdt{M) for twM=Rd
(
ð7Þ
We then compute the CPD based on Eq. 14 and perform a two
parameters fit in terms of Rd and M (see Figs. 3 and S2).
We have also analyzed similar data reported in Ref. [29] for the
growth of MSC isolated from human bone marrow for the iliac
crest (BM) and from the femoral head (HIP) (see Fig. 2). Although
significant fluctuations between donors are revealed, the results
show in general a decrease of the parameterM with the age of the
donor (see Fig. 4), older people have fewer generations of
reproduction before senescence. The plot also shows for donors
of similar age that M is smaller for BM-MSC than for HIP-MSC,
suggesting that the former are more prone to become senescent.
On the other hand, the cell division rate fluctuates around the
value of Rd~0:5 divisions/day, as reported in Ref. [27], without
any apparent correlation with age.
Cancer growth and senescence
In recent publications, one of us identified aggressive subpop-
ulations expressing two stem cell markers, ABCG2 [9] and
CXCR6 [16], in human melanoma cell lines, making this tumor a
suitable candidate to test our theory. Here, we analyze the level of
expression of the senescence marker b{gal in three human
melanoma cell lines, WM115, IGR39 and IGR37 [9,16]. IGR39
and IGR37 cells have been sorted into two subpopulations
according to the expression of the ABCG2 marker [16]. In Fig. 5A
and Table S1, we report the level of the b{gal senescent marker
as a function of time for ABCG2 positive (ABCG2+) and negative
cells (ABCG22). In both cases, we observe an increase in the
percentage of b{gal positive cells after 80–90 days of growth
followed by a decrease to the initial level after 120 days (see
Table S1). While the data follow a similar trend for the two
subpopulations, the peak for IGR39 ABCG22 cells is much
higher, reaching 90% of the cells. In order to confirm that the
difference in the expression of the senescence marker is related to a
different proliferative behavior for the two subpopulations, in
Fig. 5B we report the long-term growth curves corresponding to
IGR39. The results show that ABCG2+ cells grow substantially
more than ABCG22 cells (i.e. 23 times more). Furthermore, the
Figure 2. Dynamics of cell fractions. (a) The growth of the cell population obtained in the model for E~0:7, q~0:1, M~20 and different values
of the initial fraction of CSCs f 0CSC as a function of the number of generations N . (b) The evolution of the fraction of senescent cells corresponding to
the same parameters.
doi:10.1371/journal.pcbi.1002316.g002
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peak percentage of b{gal coincides in time with a marked slow
down in the growth (Fig. 5). When the level of b{gal expression
falls back to the initial value, growth is also restored (Fig. 5B).
These data can be described by our theoretical model, if we
assume that ABCG2+ and ABCG22 data are only distinguished
by a different initial fractions of CSCs f 0CSC . Fitting simultaneously
the growth curves and the b gal concentrations with the model
(see Fig. 5 and Materials and Methods for details), we obtain
f 0CSC~0:63+0:05% for ABCG22 and f
0
CSC~16+1% for
ABCG2+ cells. Hence, our model suggests that expression of
ABCG2 is strongly correlated with CSCs (almost a factor of thirty),
but only a relatively small fraction of ABCG2 expressing cells are
CSCs. Notice that the final CSC fraction is different from the
initial one: using the fit parameters we estimate f?CSC~0:2%. As
shown in Fig. 5A the fraction of senescent cells predicted by the
model is in good agreement with the experimental data, predicting
a large senescence peak for ABCG22 cells. Notice that we could
easily find parameters producing a clear peak in the b{gal
concentration also for ABCG2+ cells. Our multicurve fit, however,
is dominated by the (higher precision) growth curves and the
resulting best fit parameters yield no peak in the b{gal plot. For
ABCG22 cells, the peak in the theory curves arises after M
generations. The experimental peak in senescence and the
associated dip in doubling rate after *38 generations directly
implies a long-term memory of the initial preparation, embodied
by our senescence generation M, a parameter that we expect may
be smaller for other growth conditions and tumor types.
Senescence in the stochastic model of cancer growth
The peak in cellular senescence is quantitatively described by
the hierarchical model and it would be hard to reconcile this result
with the stochastic cancer model, where cancer cells are not
organized hierarchically. To illustrate this point, we reformulate
the stochastic model in mathematical terms assuming that
Figure 3. Growth curves of mesenchymal stem cells (BM). The growth of populations of MSC isolated from the bone marrow from the iliac
crest in terms of cumulative population doublings are fitted by the model. Experimental data are obtained from Ref. [28]. The best fit is obtained
varying M and Rd in Eq.7.
doi:10.1371/journal.pcbi.1002316.g003
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senescence can only occur as a result of random mutation. In this
model, we distinguish between two cell populations, cancer cells
(CC) and senescent cells. CC duplicate with probability 1{p{q,
die with probability q and become senescent with probability p,
while senescent cells do not duplicate but can die with probability
q. The average numbers of CC CN and senescent cells DN after N
generations follow recursion relations
CN~2(1{p{q)CN{1 ð8Þ
DN~(1{q)DN{1zpCN{1: ð9Þ
We can solve the recursion relations explicitly obtaining:
CN~½2(1{p{q)NC0 ð10Þ
DN~
p(1{q)
1{2p{q
 
(½2(1{p{q)N{½1{qN )C0, ð11Þ
where we have assumed for simplicity that D0~0. The solution
implies that the number of CC grows as long as 2(1{p{q)w1
and shrinks otherwise, yielding a condition for tumor progression.
Dividing CN and DN by the total population size CNzDN , we
obtain the relative fractions fCC and fSC of CC and senescent cells,
respectively. In the asymptotic limit (i.e. large N), we obtain
Figure 4. Effect of the donor age on cell senescence. The value of
the parameter M obtained in Fig. 3 as a function of the age of the
donor for MSC isolated from bone marrow from iliac crest (BM) and
femoral head (HIP). The decrease of M with age indicates that for older
donors cell senescence occurs more rapidly. HIP-MSC show a larger
value ofM than MSC-BM. We report our estimates for the parameter Rd
in the inset, showing values compatible with Rd~0:5 reported in Ref.
(26) and no significant age dependence.
doi:10.1371/journal.pcbi.1002316.g004
Figure 5. Growth and senescence of IGR39 ABCG2+ and ABCG22 human melanoma cells. Panel A shows the fraction of b{gal positive
cells for ABCG2+ and ABCG22 cells. In both cases, senescence increases rapidly after 90 days; the fraction reaches higher values for ABCG22 cells.
After 100 days, however, the fraction drops down to the asymptotic values. Panel B shows the corresponding long-term growth curves, compared
with predictions of the model, using the best fit parameters, used also for solid lines in Panel A. Panels C–F display b{gal staining for ABCG22 (C–D)
and ABCG2+ cells (E–F) at different stages: at the beginning (C and E) and at the time of the fraction peak (D and F). The fractions of b{gal positive
cells (shown in green) is largest in panel D.
doi:10.1371/journal.pcbi.1002316.g005
Senescent Cells in Growing Tumors
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steady-state solutions
fCC~
1{2p{q
1{p{q{pq
for 1{2p{qw0
0 for 1{2p{qv0
8<
: ð12Þ
fSC~
p(1{q)
1{p{q{pq
for 1{2p{qw0
1 for 1{2pv0 and q~0
0 for 1{2p{qv0 and qw0
8><
>: ð13Þ
The approach to the steady-state is reported in Fig. 6A and the
steady-state solutions are plotted in Fig. 6B in the case q~0. These
results show that the fraction of senescent cells should evolve
rapidly towards a steady state in way that is incompatible with the
experiments, providing additional evidence supporting the exis-
tence of CSCs in melanoma. The present stochastic model is
clearly oversimplified and one could think of more elaborate
models involving heterongeneous cell populations without a
hierarchy. We do not see, however, how we can explain a peak
in senescence after 90 days without assuming the presence of at
least two distinct subpopulations one of which undergoes
senescence after this long interval.
Senescence in tumor xenografts
In Fig. 7, we report the evolution of the fraction of senescent
cells in human melanoma WM115 cells according to the b{gal
marker. Fig. 7 shows an increase in the fraction of cells expressing
this marker, reaching more than 40% after 80 days of cultivation.
We find a similar level of b{gal also in tumor xenografts after 60
days (Fig. 7D). This confirms that our finding of senescent
melanoma cells is not restricted to growth in vitro.
Hypoxia does not affect growth of melanoma cells
In order to confirm that the observed cell senescence in
xenografts (Fig. 7) is not due to hypoxia, we grow WM115 cells
under normal or hypoxic conditions (see Materials and methods).
Only a slight inhibition on cell growth was observed 48 hrs after
incubation under hypoxic condition. This behavior is explained by
the induction of the hypoxia inducible factor{1a (HIF{1a) after
18 hours of hypoxic conditions (see Fig. 3). HIF{1a is a
pleiotropic transcription factor typically activated in response to
low oxygen tension as well as other stress factors in normoxic
conditions. Upon activation HIF{1a mediates the transcriptional
activation of target genes involved in a variety of processes
comprising stress adaptation, metabolism, growth and invasion,
but also apoptotic cell death. While we cannot exclude that some
form of environmental stress factor affect our results, we conclude
that hypoxia is not a likely cause for the senescence we observe in
xenografts; our in vitro cells do not experience hypoxia.
Survivin reverses senescence
Since it has been recently shown that survivin allows cells to
escape senescence [30], we transfect IGR37 ABCG22 cells at the
peak of b{gal (corresponding to the 98th day for IGR37 cells, see
Table S1) with a survivin-GFP or GFP alone [31]. We then
quantify the resulting senescence with b{gal activity and visualize
cell proliferation with crystal violet assays (see supplement for more
details). In Fig. 8A, we show that the overexpression of survivin
induces a dramatic decrease of b{gal activity. Importantly, under
the same conditions survivin enhances cell proliferation as shown
Figure 6. Senescence in the stochastic model of cancer growth. A) Evolution of the fraction of senescent cells as a function of the number of
generationsN as a function of p (compare with Fig. 2B for the CSC model) B) The asymptotic fractions of senescent cells and cancer cells as a function
of the probability p for a cell to become senescent. For pw0:5, all cells asymptotically become senescent and the tumor stops growing. (compare
with Fig. 1B for the CSC model).
doi:10.1371/journal.pcbi.1002316.g006
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by the colony size distributions (Fig. 8B), the number of colonies
and the fraction of area covered by colonies (see Table S2). The
effect of survivin is absent for unsorted IGR37 cells when the level
of b{gal is low (see Fig. 8B). Moreover, when the percentege of
b{gal positive cells is below the peak the effect is very small (see
Fig. 5). These data provide a further confirmation of the presence
of senescent cells in growing tumors.
Simulations of cancer treatments
It is illuminating to use the CSC model to simulate the effect of
a treatment on the progression of a tumor. We consider two
possible strategies: (i) try to stop tumor growth by stimulating cell
senescence, and (ii) eradicate the tumor by inducing cell death.
Case (i) can be described by decreasing the parameter M,
representing the number of generation needed for a CC to turn
senescent. The responses to treatment is summarized in Fig. 9A
showing that the tumor size stops growing for a short while,
but eventually the growth resumes at the previous rate. This is
due to the action of CSC, whose fractional population increases
dramatically in response to the treatment and sustains cancer
growth. Our model quantifies the common-sense statement that if
the cancer stem cells are the only parties that double forever, then
a treatment that does not remove them will be fruitless in the long
term. Case (ii) can be described by introducing a parameter p, as
the probability that a CC cell dies (before senescence). If we
assume that CSCs are drug resistant and therefore do not die, we
predict that the tumor size would initially shrink, but the growth
would starts again after some time (Fig. 9C), due to the persistent
growth of the CSC subpopulation (Fig. 9D) Again, the model
predicts that the only possible strategy to stop cancer growth is to
target CSCs.
Discussion
The present results have powerful implications for our picture of
cellular senescence in tumors. The stochastic cancer model
suggests that since cancer cells proliferate indefinitely, they must
have evaded senescence by some yet unknown biological
mechanism. Our results show instead that cancer cells in general
become senescent, but this fact is ultimately irrelevant for tumor
progression since long-term proliferation eventually resumes. This
finding can be explained by the hierarchical cancer model where a
subpopulation of CSCs drives tumor growth and the other cancer
cells turn senescent after a fixed number of duplications. The peak
in cell senescence should correspond precisely to the time at which
the initial population of cancer cells turn senescent slowing tumor
growth. At this point, CSCs are able to restart the growth process
by symmetric duplication leading eventually to the decrease of the
fraction of senescent cells as observed in the experiments. It would
be hard to reconcile our experimental data with the conventional
cancer model hypothizing that a random mutation would lead to
massive senescence roughly at the same time for all the different
cancer cell populations considered. The fact that CSCs do not
become senescent is probably a signature that they originate from
Figure 7. Cellular senescence in human melanoma WM115 cells. In panel A the presence of senescent cells in WM115 cells is quantified by
the fraction of b{gal positive cells which we report at the beginning of the growth, at its peak and in tumor xenograft. The mean is taken over five
independent determinations and the standard error is reported. Panel B shows b{gal staining (shown in blue) at the beginning (start), at peak and in
tumor xenograft after 60 days.
doi:10.1371/journal.pcbi.1002316.g007
Senescent Cells in Growing Tumors
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normal stem cells and are therefore already immortal. This
observation may have implications for therapeutic strategies trying
to stop tumor growth by inducing senescence: such an approach is
bound to fail unless senescence is induced in CSCs.
The data on the ABCG2 sorted population can be explained by
the hierarchical cancer model if we assume that ABCG2+ and
ABCG22 data are distinguished by a different initial fractions of
CSCs. A larger fraction of CSCs in ABCG2+ cells should reduce
the occurrence of senescence and increases proliferation with
respect to ABCG22 cells. Furthermore, the observation that both
cell populations eventually resume their growth at the same rate
suggests that some CSCs are also present in ABCG22 cells, whose
growth would otherwise stop. This implies that while ABCG2 is
able to select a CSC rich population, by itself it is not a clean
sorting criterion. This is in agreement with the results of Ref. [16]
showing that ABCG22 cells yield a tumor xenograft in
immunodeficient mice that is smaller than the one produced by
ABCG2+ cells. The fact that ABCG2 is not an absolute CSC
marker implies that its expression is reversible after sorting. We
have checked this by sorting ABCG2+ and ABCG22 cells after
139 days finding that both express ABCG2 (with percentage
0.92% and 0.45%, respectively). The same problems are likely to
affect putative CSC markers shown in the literature to be
reversibly expressed and hitherto considered incompatible with
the CSC model [18]. Similar observations in breast cancer cells
have been recently interpreted as a signature of stochastic
phenotypic switching, assuming that CC have a small probability
to revert to the CSC state [19]. The same data could possibly be
interpreted in our framework by assuming that the marker was not
perfect. It would be interesting to develop quantitative tools to
distinguish between phenotypic switching and imperfect markers.
The presence of CSC in melanoma is debated because
conflicting data are reported in the literature [14,17,18] showing
that slightly different assay conditions lead to different CSC
fractions, that can sometimes be relatively large [17]. There is in
fact no reason to believe that the CSC population must be small.
This idea comes from the analogy with tissue stem cells that
replicate homeostatically, keeping their population constant either
by asymmetric division or stochastically [6,7], leading to a
vanishing concentration of stem cells in the total cell population.
CSCs do not replicate homeostatically and therefore their
population grows exponentially. Changes in assay conditions can
change the duplication rate of CSC, leading for extreme
conditions (i.e. for example the use of matrigel, mice permissive
Figure 8. Effect of survivin on senescence. IGR37 ABCG22 cells were grown until the peak of b{gal (98 days see Table S1) and then transfected
with a plasmid containing cytoplasmic-survivin-GFP or GFP alone. The next day the cells were plated for b{gal activity (50000cells=35mm2 well) and
crystal violet (200 cells per well) assays. In panel A, we show the percentage of b{gal positive cells for untransfected, GFP and GFP-survivin cells. The
histogram shows the mean of five independent determination+ S.E. Represenative images of b{gal staining (shown in green) are reported for GFP
and GFP-survivin cells. In panel B, we show the distribution of colony sizes from crystal violet assay for GFP and GFP-survivin cells, showing a marked
increase in proliferation. Such an increase is not detected for unsorted IGR37 cells, transfected at the beginning of the experiment, for which the
percentage of b{gal positive cells is already low.
doi:10.1371/journal.pcbi.1002316.g008
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conditions etc.) to a relatively large concentration of CSCs,
perhaps resolving previous controversies [14,17,18].
Materials and Methods
Cell lines
Human IGR37 cells were obtained from Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmbH and cultured as
previously described [16]. IGR39 was derived from a primary
amelanotic cutaneous tumor and IGR37 was derived from an
inguinal lymph node metastasis in the same patient. Human
primary melanoma WM115 (ATCC CRL 1675) was cultured as
in previous work [9].
Flow cytometry
Cells were analyzed for fluoroscein isothiocyanate (FITC)
mouse anti-human ABCG2 (R&D Systems, Minneapolis, MN)
expression. All samples were analyzed using one- or two-color flow
cytometry with non-specific mouse IgG used (Invitrogen, Carls-
bad, CA) as isotype controls. For each flow cytometry evaluation, a
minimum of 5|105 cells were stained and at least 50000 events
were collected and analyzed (106 cells were stained for sorting).
Flow cytometry sorting and analysis was performed using a
FACSAria flow cytometer (Becton, Dickinson and Company, BD,
Mountain View, CA). Data were analyzed using FlowJo software
(Tree Star, Inc., San Carlos, CA).
Senescence associated b{gal assay
Expression of pH-dependent senescence associated b{gal
activity was analysed simultaneously in different passage of cells
using the Senescence galactosidase Staining Kit (Sigma) according
to the manufacturers protocol.
Tumor formation analyses and isolation of single cells
from melanoma biopsy
5|105 cells were injected subcutaneously into five-week-old
NOD-SCID mice (Charles River Laboratories, Boston, MA).
Animals were maintained on standard laboratory food ad libitum
fed and free access to water. Tumor mass was excised after two
months and digested with 0.2% collagenase type I (Gibco), 0.2%
bovine serum albumin (BSA; SIGMA, St. Louis, MO) for
30 minutes at 370C on an orbital shaker. Cells are maintained
in culture for no more than two passages.
Growth under hypoxic condition
WM115 cells were grown in standard medium under normal or
hypoxic conditions (99.8% CO2/0.2% O2) for up to 48 hours.
Figure 9. Simulated response to drugs in the CSC model. In panel A, we show the response of the model to a senescence inducing drug. The
strength of the treatment is controlled by the parameter M , that in normal conditions we set to be M~20. To simulate the effect of the drug, M is
reduced to M~10 for a weak treatment and M~2 for a strong treatment. The growth of the tumor is slowed down for a short period and then
restart as before. Panel B shows that the fraction of drug induced senescent cells rapidly decreases to the level of the control. This is due to the CSC
activity. In panel C, we show a simulation the effect of a cell death inducing drug. Here weak treatment corresponds to a probability p~0:2 for a CC
to die, while strong is simulated by setting p~0:7. The drug leads to a rapid decrease of the tumor size, measured in terms of cumulative population
doublings. After a few generations, however, the population starts to grow again. This is due to the CSC whose fraction increases as a response to the
drug (panel D). These simulations are performed using parameters characteristic of IGR39 cells.
doi:10.1371/journal.pcbi.1002316.g009
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Total RNA was extracted from WM115 cells or prostate cancer
cell lines (PC-3 used as control) [32] under normal and hypoxic
conditions. Reverse transcription (RT)-PCR reactions were done
as previously described [16]. The oligonucleotide primer sequenc-
es and gene-specific PCR amplification programs used are
following: sense 5
0
-CCTATGTAGTTGTGGAAGTTTATGC;
antisense 5
0
-ACTAGGCAATTTTGCTAAGAATG for 40 cycles
at 950C for 30 s, 600C for 15 s, and 720C for 30 s. The integrity of
each RNA and oligodeoxythymidylic acid-synthesized cDNA
sample was confirmed by the amplification of the b-actin
housekeeping gene. Ten microliter of each RT-PCR sample was
run on a 2% agarose gel and visualized by ethidium bromide
staining.
Survivin overexpression
200000 cells were plated on 6 multiwell and the day after
transfected by lipofectamin with cytoplasmic survivin-GFP
plasmid or GFP (both plasmids were a gift of Dr Wheatley,
[31]). 24 hours later the GFP-positive cells were counted by flow
cytometry. More than 95% of cells were GFP-positive. These cells
were immediately used for crystal violet or b{gal actosidase
assays.
Crystal violet staining cells and cluster analysis of the
colonies
Cells were plated on 6 multiwell and stained after 8 days.
Briefly, they were fixed with 3.7% paraformaldeide (PFA) for
5 minutes and then stained for 30 min with 0.05% crystal violet
solution. After two washings with tap water, the plates were
drained by inversion for a couple of minutes and then
photographed. To quantify cell proliferation, we threshold the
images and apply the Hoshen-Kopelman algorithm to identify
individual clusters (see Fig. 4 for a visual explanation of the
method). We then compute the number of colonies, the area
fraction covered by colonies (see Table S2) and the colony size
distribution (see Figs. 8B and S5). The last method is the most
accurate and complete, avoiding possible experimental artifacts
due to local cell detachments.
Growth curves
Long-term growth curves are obtained by splitting the cells at
each passage and rescaling the result of the counting by an
appropriate factor. Cells are counted using a burken chamber in
the presence of trypan blue. It is convenient to express the growth
curves in terms of cumulative population doublings (CPD),
expressing the number of times the populations has doubled.
CPD is directly related to the number of cells ntot(t) at time t by
the expression:
CPD(t)~ log (ntot(t)=ntot(0))= log 2; ntot(t)~ntot(0)2
CPD(t) ð14Þ
where ntot(0) is initial number of cells.
Fitting experiments with the CSC model
In order to fit the data with model, the total number of cells can
be expressed as the sums of two terms ntot(t)~S
0f (t)zcg(t)
derived from Eq. 2 and Eq. 3, respectively. In particular, we have
f (t)~
2
1zE
 M
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Furthermore, we can also compare the model with the b{gal
concentration, assuming that it is equal to the fraction of
senescent cells. The experimental comparison involves the fit of
four curves in terms of the parameters M, Rd , E, q and c. Since
ABCG2+ and ABCG22 cells only differ by their relative fraction
of CSC, we use the same values of M, Rd , E, q for the two
subpopulations and vary only the parameter c. We thus perform
a multiple curve fitting in which the two growth curves and the
two b{gal curves are fitted simultaneously in terms of six
parameters (M, Rd , E, q, c(z) and c({)), where c(+) is the value of
c for ABCG2+ cells. To this end, we use the pyFitting software
(https://github.com/gdurin/pyFitting) developed by G. Durin.
The result is
Rd~0:38+0:04 ð17Þ
M~37:7+0:1 ð18Þ
E~0:71+0:01 ð19Þ
q~0:38+0:04 ð20Þ
c(z)=S0~0:13+0:01 ð21Þ
c({)=S0~4:1+0:3 ð22Þ
with a reduced x2 of 14:3. In Table S3, we report the covariance
matrix and the t-statistic.
We can express the parameters c(z) and c({) in terms of the
initial fractions of CSC as f 0CSC~S
0=(S0zc(+)(Mz1)) for
positive and negative cells, where the arbitrary scale S0 is set
equal to one in the fits. We obtain
f 0CSC~0:63+0:05% for ABCG2{ ð23Þ
f 0CSC~16+1:% for ABCG2z ð24Þ
Hence the ABCG2+ cells have more CSCs than ABCG22 cells,
as expected. We have also checked how much the choice of the
initial condition affect the results. For simplicity, we have imposed
a uniform distribution of C0k (for kw0) to obtain a closed form
solution (Eqs. 2–3). To assess the robustness of our results, we have
compared the growth curves obtained under this assumption with
those obtained using the same fit parameters and C0k imposed as
the steady-state solution of the model with the same parameters
but smaller M. The resulting curves are very close to each other
indicating that at least for this case there is a weak dependence on
the initial conditions.
ð16Þ
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Supporting Information
Figure S1 Asymptotic fractions of CSCs and senescent
cells in the model. The asymptotic fraction of CSCs (A) and
senescent cells (B) as a function of the proliferation parameter E
and for different values of the number M of duplications needed
by cancer cells to become senescent and of the probability of cell
death q. Unlike the fraction of CSC, the fraction of senescent cells
does not depend on M.
(TIFF)
Figure S2 Growth curves of mesenchymal stem cells
(HIP). The growth of populations of MSC isolated from the bone
marrow from the femoral hip in terms of cumulative population
doublings are fitted by the model. Experimental data are obtained
from Ref. [29]. Cell populations refer to donors with different
ages. The best fit is obtained varying M and Rd in Eq. 7.
(TIFF)
Figure S3 Hypoxia inducible factor. RT-PCR of HIF{1a
(145bp) of WM115 cells grown under normal or hypoxic condition
(from 18 to 48 hrs) and PC-3 cells as positive control.
(EPS)
Figure S4 Cluster analysis of crystal violet assay. A) To
analyze the crystal violet assay, we first photograph the multiwell
and isolate a single well. B) Using the image analysis software
Gimp we select by color the spots, eliminate the background and
threshold the remaining spots in order to obtain a two color image.
C) We apply the Hoshen-Kopelman cluster algorithm to identify
individual colonies, recolored here with random colors for
visualization purposes.
(TIFF)
Figure S5 Effect of survivin on senescence away from
the peak of b”gal. we show the distribution of colony sizes
obtained from crystal violet assay for untransfected, GFP and
GFP-survivin cells. In this experiment 500 cells were plated after
88 days of cultivation (see Table S2). We see a small effect due to
GFP and survivin.
(TIFF)
Table S1 Evolution of senescence marker. The evolution
of the percentage of b{gal positive cells for ABCG2 sorted
IGR39 and IGR37 cell populations.
(PDF)
Table S2 Crystal violet assays. A summary of the results
obtained with the crystal violet assay for GFP and GFP-survivin
transfected cells at different stages of the growth. We report the
total number of colonies and the fraction of area covered by
colonies.
(PDF)
Table S3 Fit covariance matrix. The covariance matrix and
the t-statistics of the joint fit of the growth curves and b{gal
concentration with the CSC model.
(PDF)
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